Back to News
Market Impact: 0.2
Encoded Therapeutics Presents Updated Data from POLARIS Phase 1/2 Trials of ETX101 Gene Therapy in Dravet Syndrome at the 16th European Epilepsy Congress
Source: Business Wire
Healthcare & BiotechTechnology & Innovation
Encoded Therapeutics presented updated Phase 1/2 POLARIS trial data for its ETX101 gene therapy candidate in Dravet syndrome at the European Epilepsy Congress. The article provides no efficacy, safety, or financial results, limiting assessment of the program's clinical or valuation impact.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
More News
- Vertex reports positive IgAN trial data, FDA decision due Nov. 30
- The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
- Elon Musk’s dangerous grip on outer space
- J&J prostate cancer drug shows promising tumor responses in early trial
- Ukraine Says Restrictions on Starlink Speed Have Been Lifted
- AI agents could disrupt bank deposits. Why Wall Street may be overreacting
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- How to Analyze SEC Filings With AI: A Verification-First Guide
- AI for IR Street Intelligence: Notes, Estimates, and Peers